Journal of Oncology / 2008 / Article / Tab 2

Clinical Study

CYP1A1, mEH, and GSTM1 Polymophisms and Risk of Oral and Pharyngeal Cancer: A Spanish Case-Control Study

Table 2

Risks for oral and pharyngeal cancers associated with polymorphisms in genes CYP1A1, mEH, and GSTM1.

Gene Cases Controls OR crude (CI 95%)* OR adjusted (CI 95%)+

All cancers

CYP1A1

No mutated1.001.00
Mutated0.72 (0.10–5.28)1.68 (0.18–15.70)

mEH (139 )

His/His1.001.00
His/Arg0.95 (0.52–1.75)0.81 (0.38–1.71)
Arg/arg4.30 (0.46–40.07)4.45 (0.39–50.45)

GSTM1

Present1.001.00
Absent1.16 (0.73–1.99)1.25 (0.65–2.40)

Oral cancer

CYP1A1

No mutated5364 (97%)1.001.00
Mutated02 (3%)

mEH (139 )

His/His39 (73,6%)88 (67,7%)1.001.00
His/Arg12 (22,6%)41 (31,5%)0.74 (0.34–1.58)0.54 (0.21–1.41)
Arg/arg2 (3,8%)1 (0,8%)3.44 (0.29–40.16)4.32 (0.32–58.63)

GSTM1

Present26 (49,1%)68 (52,3%)1.001.00
Absent27 (50,9%)62 (47,7%)1.14 (0.60–2.19)1.20 (0.56–2.18)

Pharyngeal cancer

CYP1A1

No mutated37 (94,9%)64 (97%)1.001.00
Mutated2 (5,1%)2 (3%)1.74 (0.23–12.92)4.06 (0.43–38.24)

mEH (139 )

His/His24 (61,5%)88 (67,7%)1.001.00
His/Arg13 (33,3%)41 (31,5%)1.27 (0.58–2.80)1.07 (0.42–2.71)
Arg/arg2 (5,2%)1 (0,8%)5.58 (0.47–66.10)5.74 (0.34–97.71)

GSTM1

Present19 (48,7%)68 (52,3%)1.001.00
Absent20 (51,3%)62 (47,7%)1.20 (0.58–2.48)1.44 (0.61–3.37)

*Adjusted for age.+Adjusted for age, smoking, and alcohol intake.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.